Emerging concepts, a growing knowledge base, and new targets are changing the way mantle cell lymphoma is treated and managed, according to Mark Roschewski, MD, of the Center for Cancer Research National Cancer Institute at the National Institutes of Health.
"With more understanding of the biology about what makes this lymphoma different than others, we see changes," Roschewski said. "We have seen a lot of changes in this particular disease even in the last year. I think this bodes well for the future of how we are going to manage patients."